Pharma news, pharmaceutical news, Pharma Industry News, India Pharmaceutical Industry

Rs.1230 cr understated liability as of Sept 30: Raju
Q2 Accrued interest of Rs.376 cr non-existent: Raju
Satyam carries inflated cash balance of Rs.5040 cr: Raju
Rs.1230 cr understated liability as of Sept 30
Q2 Accrued interest of Rs.376 cr non-existent
Rs.588 crores artificial cash in Satyam books: Raju
Satyam carries inflated cash balance of Rs.5040 cr
Satyam chairman Ramalinga Raju resigns from board
Still testing authenticity of communication from Satyam
Will take action against auditors if involvement found
Auditors accountable for financial situation: SEBI
Need for investors to know the truth: SEBI
Violations across several laws: SEBI
Satyam issue has serious implications: SEBI
Wrong doings at Satyam should be probed in detail
LIC remains a long term investor in Satyam
Liability also falls on independent board members
Satyam news a company specific issue only
Banks to outperform other sectors in Q3
Markets may fall on negative triggers coming from Q3
Results could be 'slightly' better vs expectations
Shocked at the startling revelations from Raju
Valuations in unlisted space still remain high
India still a small fraction of Asian PE activity
Would look to raise funds from institutions in late 2009
PE players continue to park funds into quality investment
Growth in exports from Asia in H2'CY09
U.S. economy could remain subdued in 2009
Earnings de-growth remains the key trigger for current qtr
Strike to impact Panipat, Gujarat refineries ops: NW

Updated: 06/01/09 | 12:06 AM IST

Pharma

The saga of Sun Pharma's protracted battle to acquire control of Israel’s Taro Pharma seems to be approaching its final hours. Sun, in a last ditch attempt at an early resolution has proposed two options.

Comments: Read (0) Post

Pharma too not immune to meltdown

The global meltdown woes have even reached one of the most insulated sectors—Pharma. However, even as global markets are non-growing for many Indian players, domestic markets prove to be an anchor with steady growth at a volatile time.

Comments: Read (0) Post

Piramal Health buys Minrad for $40 mn

Healthcare company Piramal Healthcare on Tuesday announced acquisition of US-based Minrad International for Rs 188 crore, thus, re-emphasising the possibility of increased M&A activities in a mature pharma market like the US.

Comments: Read (0) Post

Wockhardt, Manipal in preliminary merger talks

It is believed that Bangalore-based Manipal Hospital is in the process of discussing merger with leading healthcare provider Wockhardt Hospitals.

Comments: Read (0) Post

Pharma R&D spending suffers as firms cut costs

There's no easy way to combat recession than cut costs. But with the rising trend of pharma companies going for cut in R&D spending, will consumers have to live with drugs and medicines which were developed a long time ago?

Comments: Read (0) Post

No intention of buying Ranbaxy: Pfizer

The Lipitor deal had further added to the speculation of Pfizer picking up a stake in Ranbaxy. But Pfizer on Wednesday told NDTV that it has no intention of picking up stake in Ranbaxy.

Comments: Read (0) Post

Global Crisis

Export woes deepen, contracts 1.6% in Dec

Exports fell for the third straight month, posting a negative growth of 1.6 per cent in December 2008 as demand from key markets continued to remain sluggish.

More : Export units to lose 1 cr jobs by March: FIEO | Toyota to halt Japan output for 11 days | US bankruptcy filings jump by 33% in '08

Market Watch

Graphs

Stocks